ArticleHuman vaccines & immunotherapeutics2026
Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates the allergic responses in a murine allergic rhinitis model.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates the allergic responses in a murine allergic rhinitis model.Human vaccines & immunotherapeutics · 2026Article
- Serum metabolomic profiling identifies taurolithocholic acid as a predictor of HDM-SCIT response in allergic rhinitis: clinical discovery and experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous immunotherapy has several limitations, including the long dose escalation period, frequent injections and risk of adverse reactions. Crude extracts used for immunotherapy can contain unrecognized immunostimulatory components or induce neosensitization. Therefore, in this study, we aimed to develop a new efficient method to induce allergen-specific immune tolerance using Dermatophagoides pteronyssinus (Der p) 1-containing nanoparticles. We developed two different types of allergen-containing poly(lactic-co-glycolic) [PLGA] nanoparticle vaccines: Der p 1-encapsulated and Der p 1-conjugated vaccines. House dust mite (HDM)-sensitized mice were administered positive control (PC), PLGA (vehicle control), encapsulated vaccine (EV), and conjugated vaccine (CV) via intravenous injections one week after sensitization. Subcutaneous immunotherapy group received three subcutaneous HDM extract injections at two-day intervals. After challenge, we compared the rhinitis symptoms, immunoglobulin (Ig) levels, and histopathology of the nasal mucosa and analyzed splenocyte cultures for cytokine production and regulatory T cell activation. EV and CV groups exhibited improved nasal symptoms and lower ear swelling and inflammation in the nasopharyngeal lavage and nasal tissues than PC group. Serum HDM-specific IgG1 levels were higher in EV and CV groups than in PC group. No changes were observed in the total and HDM-specific IgE levels in EV group. EV group exhibited lower interleukin-4, -5, -13, and -17 levels and higher interleukin-10 and interferon-γ levels than PC group. The two vaccinated groups exhibited significantly higher regulatory T cell activation than PC group. Overall, intravenously administered Der p 1-containing nanoparticles alleviated the allergic responses and induced tolerance in a murine allergic rhinitis model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.